25 results
10-Q
2024 Q1
IMCR
Immunocore Holdings plc
8 May 24
Quarterly report
7:00am
compensation expense, for selling, corporate and other administrative and operational functions including finance, legal, human resources, commercial
DEF 14A
IMCR
Immunocore Holdings plc
12 Apr 24
Definitive proxy
4:20pm
into employment agreements with our executive officers based in the United States and a contract of employment with Ms. St. Leger, our Chief Human Resources Officer … ., Ph.D.
Head of Research and Development
Tina St. Leger
Chief Human Resources Officer
Biographical information for Dr. Jallal is included above
PRE 14A
IMCR
Immunocore Holdings plc
2 Apr 24
Preliminary proxy
4:45pm
into employment agreements with our executive officers based in the United States and a contract of employment with Ms. St. Leger, our Chief Human Resources Officer … ., Ph.D.
Head of Research and Development
Tina St. Leger
Chief Human Resources Officer
Biographical information for Dr. Jallal is included above
10-K
2023 FY
IMCR
Immunocore Holdings plc
28 Feb 24
Annual report
7:33am
, information systems, facilities, human resources or administrative support. Further, we have 139 employees (28%) who hold Ph.D. degrees. None of our … and disease targets require substantial technical, financial and human resources, whether or not they are ultimately successful. For example, we develop
10-K
2023 FY
EX-10.14
IMCR
Immunocore Holdings plc
28 Feb 24
Annual report
7:33am
AND REPORTING STRUCTURE
You are employed in the position of Chief Human Resources Officer and your duties will be designated from time to time … are to be found on THE COMPANY’s intranet.
Study leave may be given by arrangement with your manager and Human Resources when any exams are sat.
Occasionally
6-K
EX-99.2
idi4nw
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.2
53m5y0
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.2
8gk718qov
10 May 23
Current report (foreign)
7:27am
6-K
EX-99.2
ywxocm
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
6-K
EX-99.2
kpq5 zhurrfea
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am
D
z9r76at
28 Jul 22
$140M in equity, sold $140M, 8 investors
4:57pm
6-K
EX-99.2
o90z xq36
11 May 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:08am
6-K
EX-99.2
jz0fxx6f
10 Nov 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:01am
6-K
EX-99.2
goma6ummj9
11 Aug 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:00am
6-K
EX-99.2
e268lbz9
12 May 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:00am
20-F
y1vy4ecmdhjxh 8ul
25 Mar 21
Annual report (foreign)
7:01am
20-F
EX-4.20
iwn58jeop757
25 Mar 21
Annual report (foreign)
7:01am
424B4
8z89dhze1czl95aft7
8 Feb 21
Prospectus supplement with pricing info
8:36am
F-1/A
v594b6fcdia95
3 Feb 21
Registration statement (foreign) (amended)
5:22pm